Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure

Results from the RELAX-AHF study

Gad Cotter, Adriaan A. Voors, Margaret F. Prescott, G. Michael Felker, Gerasimos Filippatos, Barry H. Greenberg, Peter Pang, Piotr Ponikowski, Olga Milo, Tsushung A. Hua, Min Qian, Thomas M. Severin, John R. Teerlink, Marco Metra, Beth A. Davison

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background Growth differentiation factor 15 (GDF-15) was found to be upregulated in patients with chronic heart failure (HF) and associated with disease severity, however, data on patients with acute heart failure (AHF) is lacking. Methods and results Levels of GDF-15 were measured at pre-specified time-points (baseline and at days 2, 5, 14, and 60) in patients enrolled in the placebo-controlled RELAXin in Acute Heart Failure (RELAX-AHF) study, which examined the effect of serelaxin in 1161 patients with AHF, systolic blood pressure >125 mmHg, and mild to moderate renal impairment. Neither baseline nor changes in GDF-15 were associated with the degree of dyspnoea or dyspnoea relief. After adjustment for baseline characteristics, baseline GDF-15 was not associated with the composite endpoint of heart failure or renal failure (HF/RF) readmission at 60 days/cardiovascular (CV) death or CV death at 180 days. In contrast, larger increases in GDF-15 levels at days 2 and 14 were associated with a greater risk of 60-day HF/RF rehospitalizations/CV death and CV death at 180 days. Serelaxin treatment was associated with significantly larger decreases of GDF-15 at days 2 and 5 than placebo. Conclusions In AHF patients enrolled in the RELAX-AHF study, increases in GDF-15 levels, but not baseline measurements, were associated with a greater likelihood of adverse outcomes. Serelaxin administration was associated with greater decreases in GDF-15 compared with placebo.

Original languageEnglish (US)
Pages (from-to)1133-1143
Number of pages11
JournalEuropean Journal of Heart Failure
Volume17
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Growth Differentiation Factor 15
Heart Failure
Placebos
Dyspnea
Blood Pressure
Renal Insufficiency
Kidney

Keywords

  • Acute heart failure
  • GDF-15
  • RELAX-AHF study

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cotter, G., Voors, A. A., Prescott, M. F., Felker, G. M., Filippatos, G., Greenberg, B. H., ... Davison, B. A. (2015). Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: Results from the RELAX-AHF study. European Journal of Heart Failure, 17(11), 1133-1143. https://doi.org/10.1002/ejhf.331

Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure : Results from the RELAX-AHF study. / Cotter, Gad; Voors, Adriaan A.; Prescott, Margaret F.; Felker, G. Michael; Filippatos, Gerasimos; Greenberg, Barry H.; Pang, Peter; Ponikowski, Piotr; Milo, Olga; Hua, Tsushung A.; Qian, Min; Severin, Thomas M.; Teerlink, John R.; Metra, Marco; Davison, Beth A.

In: European Journal of Heart Failure, Vol. 17, No. 11, 01.11.2015, p. 1133-1143.

Research output: Contribution to journalArticle

Cotter, G, Voors, AA, Prescott, MF, Felker, GM, Filippatos, G, Greenberg, BH, Pang, P, Ponikowski, P, Milo, O, Hua, TA, Qian, M, Severin, TM, Teerlink, JR, Metra, M & Davison, BA 2015, 'Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: Results from the RELAX-AHF study', European Journal of Heart Failure, vol. 17, no. 11, pp. 1133-1143. https://doi.org/10.1002/ejhf.331
Cotter, Gad ; Voors, Adriaan A. ; Prescott, Margaret F. ; Felker, G. Michael ; Filippatos, Gerasimos ; Greenberg, Barry H. ; Pang, Peter ; Ponikowski, Piotr ; Milo, Olga ; Hua, Tsushung A. ; Qian, Min ; Severin, Thomas M. ; Teerlink, John R. ; Metra, Marco ; Davison, Beth A. / Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure : Results from the RELAX-AHF study. In: European Journal of Heart Failure. 2015 ; Vol. 17, No. 11. pp. 1133-1143.
@article{b6f94038ffb94e1a83e5cccb6a1c5ad0,
title = "Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: Results from the RELAX-AHF study",
abstract = "Background Growth differentiation factor 15 (GDF-15) was found to be upregulated in patients with chronic heart failure (HF) and associated with disease severity, however, data on patients with acute heart failure (AHF) is lacking. Methods and results Levels of GDF-15 were measured at pre-specified time-points (baseline and at days 2, 5, 14, and 60) in patients enrolled in the placebo-controlled RELAXin in Acute Heart Failure (RELAX-AHF) study, which examined the effect of serelaxin in 1161 patients with AHF, systolic blood pressure >125 mmHg, and mild to moderate renal impairment. Neither baseline nor changes in GDF-15 were associated with the degree of dyspnoea or dyspnoea relief. After adjustment for baseline characteristics, baseline GDF-15 was not associated with the composite endpoint of heart failure or renal failure (HF/RF) readmission at 60 days/cardiovascular (CV) death or CV death at 180 days. In contrast, larger increases in GDF-15 levels at days 2 and 14 were associated with a greater risk of 60-day HF/RF rehospitalizations/CV death and CV death at 180 days. Serelaxin treatment was associated with significantly larger decreases of GDF-15 at days 2 and 5 than placebo. Conclusions In AHF patients enrolled in the RELAX-AHF study, increases in GDF-15 levels, but not baseline measurements, were associated with a greater likelihood of adverse outcomes. Serelaxin administration was associated with greater decreases in GDF-15 compared with placebo.",
keywords = "Acute heart failure, GDF-15, RELAX-AHF study",
author = "Gad Cotter and Voors, {Adriaan A.} and Prescott, {Margaret F.} and Felker, {G. Michael} and Gerasimos Filippatos and Greenberg, {Barry H.} and Peter Pang and Piotr Ponikowski and Olga Milo and Hua, {Tsushung A.} and Min Qian and Severin, {Thomas M.} and Teerlink, {John R.} and Marco Metra and Davison, {Beth A.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1002/ejhf.331",
language = "English (US)",
volume = "17",
pages = "1133--1143",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure

T2 - Results from the RELAX-AHF study

AU - Cotter, Gad

AU - Voors, Adriaan A.

AU - Prescott, Margaret F.

AU - Felker, G. Michael

AU - Filippatos, Gerasimos

AU - Greenberg, Barry H.

AU - Pang, Peter

AU - Ponikowski, Piotr

AU - Milo, Olga

AU - Hua, Tsushung A.

AU - Qian, Min

AU - Severin, Thomas M.

AU - Teerlink, John R.

AU - Metra, Marco

AU - Davison, Beth A.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Background Growth differentiation factor 15 (GDF-15) was found to be upregulated in patients with chronic heart failure (HF) and associated with disease severity, however, data on patients with acute heart failure (AHF) is lacking. Methods and results Levels of GDF-15 were measured at pre-specified time-points (baseline and at days 2, 5, 14, and 60) in patients enrolled in the placebo-controlled RELAXin in Acute Heart Failure (RELAX-AHF) study, which examined the effect of serelaxin in 1161 patients with AHF, systolic blood pressure >125 mmHg, and mild to moderate renal impairment. Neither baseline nor changes in GDF-15 were associated with the degree of dyspnoea or dyspnoea relief. After adjustment for baseline characteristics, baseline GDF-15 was not associated with the composite endpoint of heart failure or renal failure (HF/RF) readmission at 60 days/cardiovascular (CV) death or CV death at 180 days. In contrast, larger increases in GDF-15 levels at days 2 and 14 were associated with a greater risk of 60-day HF/RF rehospitalizations/CV death and CV death at 180 days. Serelaxin treatment was associated with significantly larger decreases of GDF-15 at days 2 and 5 than placebo. Conclusions In AHF patients enrolled in the RELAX-AHF study, increases in GDF-15 levels, but not baseline measurements, were associated with a greater likelihood of adverse outcomes. Serelaxin administration was associated with greater decreases in GDF-15 compared with placebo.

AB - Background Growth differentiation factor 15 (GDF-15) was found to be upregulated in patients with chronic heart failure (HF) and associated with disease severity, however, data on patients with acute heart failure (AHF) is lacking. Methods and results Levels of GDF-15 were measured at pre-specified time-points (baseline and at days 2, 5, 14, and 60) in patients enrolled in the placebo-controlled RELAXin in Acute Heart Failure (RELAX-AHF) study, which examined the effect of serelaxin in 1161 patients with AHF, systolic blood pressure >125 mmHg, and mild to moderate renal impairment. Neither baseline nor changes in GDF-15 were associated with the degree of dyspnoea or dyspnoea relief. After adjustment for baseline characteristics, baseline GDF-15 was not associated with the composite endpoint of heart failure or renal failure (HF/RF) readmission at 60 days/cardiovascular (CV) death or CV death at 180 days. In contrast, larger increases in GDF-15 levels at days 2 and 14 were associated with a greater risk of 60-day HF/RF rehospitalizations/CV death and CV death at 180 days. Serelaxin treatment was associated with significantly larger decreases of GDF-15 at days 2 and 5 than placebo. Conclusions In AHF patients enrolled in the RELAX-AHF study, increases in GDF-15 levels, but not baseline measurements, were associated with a greater likelihood of adverse outcomes. Serelaxin administration was associated with greater decreases in GDF-15 compared with placebo.

KW - Acute heart failure

KW - GDF-15

KW - RELAX-AHF study

UR - http://www.scopus.com/inward/record.url?scp=84955170426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955170426&partnerID=8YFLogxK

U2 - 10.1002/ejhf.331

DO - 10.1002/ejhf.331

M3 - Article

VL - 17

SP - 1133

EP - 1143

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 11

ER -